Clinical trials
for patients
Learn about available clinical trials
![](/.resources/ModuloCUN/themes/nurun/cysnet/loading.gif)
![](/.resources/ModuloCUN/themes/nurun/cysnet/loading.gif)
![](/.resources/ModuloCUN/themes/nurun/cysnet/loading.gif)
-
July 16, 2024Pamplona/MadridIn recruitmentEarly phase
XB002-101 Clinical trial to evaluate the safety and pharmacokinetics of xb002 in monotherapy and polytherapy in patients with solid tumors.
The objective of this study is to determine the DMT and/or RD to further evaluate the intravenous (i.v.) administration of XB002 in monotherapy and polytherapy in patients with advanced malignancies. -
July 16, 2024Pamplona/MadridIn recruitment
GO44457 Clinical trial to evaluate the efficacy and safety of neoadjuvant immunotherapy combinations in patients with surgically resectable hepatocellular carcinoma (MORPHEUS-NEO HCC).
The purpose of this study is to compare the effects, good or bad, that AIT (antineoplastic immunotherapy) combinations have on you and your liver cancer, to find out which treatment is best. The AIT combinations are experimental drug treatments, which means that they are not approved by health authorities for the treatment of liver cancer as neoadjuvant therapy (treatment of cancer before surgery). -
July 10, 2024Pamplona/MadridIn recruitmentEarly phase
RMC-6291-101 Clinical trial of RMC-6291 in combination with RMC-6236 in participants with advanced solid tumors with the KRASG12 mutation.
The purpose of this study is to analyze a combination of 2 new drugs called RMC-6291 and RMC-6236 (the study drugs). This study will look at the safety and antitumor effects of RMC-6291 and RMC-6236 when given together at different doses in participants with KRASG12C-mutated solid tumors. It will also analyze how their body processes RMC-6291 and RMC-6236 when they are administered together. -
July 10, 2024PamplonaIn recruitment
A35-009 Clinical Trial on the Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy.
The objective of this clinical trial is to determine the extent to which the investigational drug, AMX0035, is safe and effective for the treatment of PSP, and to determine whether it can slow disease progression. -
July 10, 2024PamplonaIn recruitmentEarly phase
IMMUWHY Trial with durvalumab (MEDI4736) odurvalumab and tremelimumab, in patients with advanced stage intrahepatic bile duct cancer (BTC) who were to receive SIRT Y-90 therapy as standard treatment.
The aim of this clinical trial is therefore to combine for the first time two treatment methods (immunotherapy with concomitant SIRT treatment) to test whether in the future it could be useful to treat bile duct carcinoma with immunotherapy and concomitant SIRT treatment. -
July 10, 2024MadridIn recruitment
B7981080 Multicenter, randomized, double-blind, placebo-controlled, Phase III clinical trial to investigate the efficacy, safety and tolerability of Ritlecitinib in adult participants with non-segmental vitiligo.
The aim of this study is to find out whether ritlecitinib is effective in the treatment of vitiligo and whether it is safe for use in humans. -
July 1, 2024Pamplona/MadridIn recruitment
D7230C00001 AZD0305 trial in participants with multiple myeloma.
The purpose of this trial is to learn whether the trial drug will be safe, tolerable and effective in the treatment of patients with multiple myeloma and also to better understand the disease being studied and the associated health problems. -
July 1, 2024MadridIn recruitment
V940-007 Phase 2/3 study of (Neo)adjuvant V940 and pembrolizumab in cSCC
The main objective is to compare V940 plus pembrolizumab with SOC with respect to EFS. -
July 1, 2024Pamplona/MadridIn recruitmentEarly phase
RAD-18-003 Phase II clinical trial in patients with advanced high-grade serous or endometrioid epithelial ovarian, fallopian tube or primary peritoneal cancer who are scheduled for neoadjuvant chemotherapy and cytoreductive surgery.
The objective is to further determine whether Radspherin® can have a positive effect on disease progression in people with ovarian cancer after surgical treatment. This study will also further evaluate the safety of Radspherin®. -
June 21, 2024PamplonaIn recruitment
J2T-MC-KGBJ Prolongation trial to evaluate the safety and efficacy of lebrikizumab in participants aged 6 months to less than 18 years with moderate to severe atopic dermatitis.
The main reason for your participation in the study is not to provide treatment for your disease, but to help find an answer to the following scientific question: The efficacy and safety of lebrikizumab when taken over a prolonged period of time.